Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.06 and traded as low as $2.81. XBiotech shares last traded at $2.84, with a volume of 29,524 shares.
XBiotech Trading Down 1.0%
The company has a market capitalization of $86.59 million, a price-to-earnings ratio of -2.63 and a beta of 0.98. The stock has a 50-day simple moving average of $3.06 and a 200-day simple moving average of $4.18.
XBiotech (NASDAQ:XBIT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On XBiotech
A number of institutional investors have recently modified their holdings of XBIT. Bank of New York Mellon Corp lifted its holdings in XBiotech by 7.5% during the 4th quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock worth $360,000 after buying an additional 6,328 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of XBiotech during the 4th quarter valued at approximately $58,000. JPMorgan Chase & Co. lifted its stake in XBiotech by 68.2% during the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 5,930 shares during the last quarter. Barclays PLC lifted its stake in XBiotech by 13.9% during the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock worth $119,000 after purchasing an additional 3,661 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in XBiotech by 15.2% in the fourth quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company's stock worth $835,000 after purchasing an additional 27,909 shares during the period. Institutional investors and hedge funds own 55.70% of the company's stock.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
